JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 42(2008) N 1 p. 64-69;
D.S. Mikhaylenko1,2, R.V. Kurynin3, A.M. Popov4, O.B. Karyakin4, M.E. Enikeev3, Yu.G. Alyaev3, M.V. Nemtsova1,2, D.V. Zaletayev1,2

VHL inactivation in sporadic clear cell renal carcinoma

1Medical Genetic Research Center, Russian Academy of Medical Sciences, Moscow, 115478, Russia
2Institute of Molecular Medicine, Sechenov Moscow Medical Academy, Moscow, 119992, Russia
3Fronshtein Urology Clinics, Sechenov Moscow Medical Academy, Moscow, 119435, Russia
4Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk, 249036, Russia
Received - 2007-02-05; Accepted - 2007-05-23

Clear cell renal carcinoma (CCRC) accounts for 75% of all renal cancer cases. The majority of CCRCs displays inactivation of the VHL suppressor gene as a result of mutations, allelic deletions, and/or methylation. Data on the effect of VHL inactivation on the prognosis in CCRC are discrepant. Comprehensive molecular genetic analysis of VHL was performed for 64 CCRCs: mutations were identified by single strand conformation polymorphism analysis and subsequent sequencing, a loss of heterozygosity was studied with two STR markers, and methylation was assessed by methylation-sensitive PCR. In total, 17 somatic mutations, including 12 new ones, were found in VHL. Allelic deletions of VHL were detected in 31.6% of cases; methylation was observed in 7.8% of cases. In total, VHL was inactivated in 46.9% of CCRC cases and in 51.7% of patients with CCRC stage I. The frequencies of mutations, loss of heterozygosity, and methylation did not correlate with clinical features of CCRC or pathological characteristics of the tumor. Studies of the molecular genetics alterations of VHL are thought to facilitate the identification of diagnostic and prognostic markers of renal cancer, e.g., the selection of an optimal panel of methylated suppressor genes.

VHL, renal cancer, somatic mutation, loss of heterozygosity, aberrant methylation



JMB-FOOTER RAS-JOURNALS